The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Second-line chemotherapy with capecitabine (CAP) and oxaliplatin (OX) in patients with pancreatic or biliary tree adenocarcinoma (ADC).
Joan Manel Mane
Disclosure not yet available
Eluska Iruarrizaga
Disclosure not yet available
Itziar Rubio
Disclosure not yet available
Eva Fonseca
Disclosure not yet available
Estibaliz Iza
Disclosure not yet available
Raquel Casas
Disclosure not yet available
Ines Marrodan
Disclosure not yet available
Mireia Martinez
Disclosure not yet available
Ricardo Fernandez
Disclosure not yet available
Sergio Carrera
Disclosure not yet available